DE60140456D1 - Aza heterocyclische derivate und ihre therapeutische verwendung - Google Patents

Aza heterocyclische derivate und ihre therapeutische verwendung

Info

Publication number
DE60140456D1
DE60140456D1 DE60140456T DE60140456T DE60140456D1 DE 60140456 D1 DE60140456 D1 DE 60140456D1 DE 60140456 T DE60140456 T DE 60140456T DE 60140456 T DE60140456 T DE 60140456T DE 60140456 D1 DE60140456 D1 DE 60140456D1
Authority
DE
Germany
Prior art keywords
sup
therapeutic use
heterocyclic derivatives
pharmaceutically acceptable
aza heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140456T
Other languages
German (de)
English (en)
Inventor
Paul Renhowe
Tim Machajewski
Cynthia Shafer
Mary-Ellen Wernette-Hammond
Sabina Pecci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE60140456D1 publication Critical patent/DE60140456D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60140456T 2000-09-01 2001-08-30 Aza heterocyclische derivate und ihre therapeutische verwendung Expired - Lifetime DE60140456D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23182900P 2000-09-01 2000-09-01
PCT/US2001/041942 WO2002018383A2 (en) 2000-09-01 2001-08-30 Aza heterocyclic derivatives and their therapeutic use

Publications (1)

Publication Number Publication Date
DE60140456D1 true DE60140456D1 (de) 2009-12-24

Family

ID=22870779

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140456T Expired - Lifetime DE60140456D1 (de) 2000-09-01 2001-08-30 Aza heterocyclische derivate und ihre therapeutische verwendung

Country Status (9)

Country Link
US (4) US6756383B2 (enExample)
EP (1) EP1313734B1 (enExample)
JP (2) JP4341949B2 (enExample)
AT (1) ATE448226T1 (enExample)
AU (1) AU2001293233A1 (enExample)
DE (1) DE60140456D1 (enExample)
ES (1) ES2334641T3 (enExample)
PT (1) PT1313734E (enExample)
WO (1) WO2002018383A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ES2302106T3 (es) * 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
CN100526312C (zh) * 2002-08-23 2009-08-12 诺华疫苗和诊断公司 苯并咪唑喹啉酮及其应用
BR0313743A (pt) * 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US7232826B2 (en) * 2002-09-30 2007-06-19 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
SG148864A1 (en) * 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
US7189716B2 (en) * 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
EP1590339A4 (en) * 2003-01-28 2007-07-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US7893096B2 (en) * 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
KR101167573B1 (ko) * 2003-11-07 2012-07-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
FR2862969A1 (fr) 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
WO2005082340A2 (en) * 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
ES2374570T3 (es) 2005-01-27 2012-02-17 Novartis Vaccines And Diagnostics, Inc. Tratamiento de tumores metastalizados.
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
ES2595363T3 (es) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US8299081B2 (en) * 2005-05-13 2012-10-30 Novartis Ag Methods for treating drug resistant cancer
CN101223157B (zh) * 2005-05-17 2013-03-06 诺瓦提斯公司 合成杂环化合物的方法
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
EP1904480A2 (en) 2005-05-23 2008-04-02 Novartis Pharma AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
WO2007011777A2 (en) 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
WO2007052058A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
JP2009517481A (ja) 2005-11-29 2009-04-30 ノバルティス アクチエンゲゼルシャフト キノリノンの製剤
EP1960547A2 (en) 2005-12-08 2008-08-27 Novartis AG Effects of inhibitors of fgfr3 on gene transcription
HUE049580T2 (hu) 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0800855D0 (en) * 2008-01-17 2008-02-27 Syngenta Ltd Herbicidal compounds
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
SI3178490T1 (sl) 2009-07-15 2022-08-31 Glaxosmithkline Biologicals S.A. Sestavki proteina F RSV-ja in postopki za pripravo le-teh
HRP20141270T1 (xx) 2009-07-16 2015-03-13 Novartis Ag Detoksificirani imunogeni escherichie coli
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
WO2011051212A1 (de) * 2009-10-28 2011-05-05 Basf Se Verwendung heteroaromatischer verbindungen als herbizide
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
HRP20190791T1 (hr) 2011-01-26 2019-06-28 Glaxosmithkline Biologicals Sa Režim imuniziranja protiv rsv
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
WO2014053521A2 (en) 2012-10-02 2014-04-10 Novartis Ag Nonlinear saccharide conjugates
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP2977374A1 (en) 2014-07-21 2016-01-27 Université de Strasbourg Molecules presenting dual emission properties
SG10202105964RA (en) * 2015-06-25 2021-07-29 Univ Health Network Hpk1 inhibitors and methods of using same
CN107935858B (zh) * 2016-10-12 2020-09-08 利尔化学股份有限公司 5-氟-2-硝基苯酚的制备方法
KR102763767B1 (ko) * 2017-11-24 2025-02-05 얀센 파마슈티카 엔브이 피라졸로피리디논 화합물
JP7329510B2 (ja) 2017-11-24 2023-08-18 ヤンセン ファーマシューティカ エヌ．ベー． ピラゾロピリジノン化合物
WO2020135483A1 (en) 2018-12-26 2020-07-02 Janssen Pharmaceutica Nv Thienopyridinone compounds
KR20230018365A (ko) * 2020-04-13 2023-02-07 유니버시티 헬스 네트워크 사이토카인 방출 증후군의 치료 방법
TW202246284A (zh) * 2021-03-10 2022-12-01 大陸商山東軒竹醫藥科技有限公司 三并環類hpk1抑制劑及其用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE290153C (enExample)
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
DE3634066A1 (de) * 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
DE3739366A1 (de) 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
AU658646B2 (en) * 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA2131528C (en) 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
AU5881394A (en) 1994-01-08 1995-08-01 Rhone-Poulenc Agriculture Limited Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO1997048694A1 (en) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
AU8816298A (en) 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
WO2000012089A1 (en) * 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
WO1999050263A1 (en) * 1998-03-31 1999-10-07 Warner-Lambert Company Quinolones as serine protease inhibitors
WO1999059636A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
WO2000020400A1 (en) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
KR100373203B1 (ko) 1999-03-31 2003-02-25 주식회사 엘지화학 새로운 큐마린계 착물 및 이를 이용한 유기 발광 소자
WO2000071129A1 (en) 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
HUP0203323A3 (en) 1999-10-19 2004-01-28 Merck & Co Inc Tyrosine kinase inhibitors and pharmaceutical compositions containing them
WO2001028993A2 (en) * 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
AU2001229254B2 (en) 2000-01-19 2006-07-27 Gill, Parkash S. Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
JP2003523390A (ja) 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2001293233A1 (en) * 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US6656942B2 (en) 2000-10-17 2003-12-02 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
JP2004536113A (ja) 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US7232826B2 (en) 2002-09-30 2007-06-19 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
KR101167573B1 (ko) 2003-11-07 2012-07-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
WO2005054183A2 (en) 2003-12-01 2005-06-16 The Scripps Research Institute Quinolinone based protein kinase inhibitors
ES2374570T3 (es) 2005-01-27 2012-02-17 Novartis Vaccines And Diagnostics, Inc. Tratamiento de tumores metastalizados.

Also Published As

Publication number Publication date
US7368459B2 (en) 2008-05-06
ATE448226T1 (de) 2009-11-15
WO2002018383A2 (en) 2002-03-07
US20070032528A1 (en) 2007-02-08
PT1313734E (pt) 2010-02-09
JP2004507543A (ja) 2004-03-11
US20020103230A1 (en) 2002-08-01
EP1313734B1 (en) 2009-11-11
US6756383B2 (en) 2004-06-29
JP4341949B2 (ja) 2009-10-14
JP2007217427A (ja) 2007-08-30
ES2334641T3 (es) 2010-03-15
US20050137188A1 (en) 2005-06-23
WO2002018383A3 (en) 2002-08-29
US20040002518A1 (en) 2004-01-01
AU2001293233A1 (en) 2002-03-13
US6759417B2 (en) 2004-07-06
US7138409B2 (en) 2006-11-21
EP1313734A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ATE180468T1 (de) Anthranilsäure derivate
EA200400893A1 (ru) N-арил-2-оксазолидинон-5-карбоксамиды, их производные и их применение в качестве антибактериальных средств
DE69835430D1 (de) Sulfonamidderivate, ihre herstellung und verwendung
DE69933573D1 (de) Chinazolinderivate als medikamente
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
KR960701878A (ko) 수용성 캄프토테신 유도체, 이의 제조 방법 및 항종양제로서의 이의 용도(Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents)
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
YU69902A (sh) Novi derivati piperazina
DK0736018T3 (da) 4,5-Diaryloxazolderivater
DK0386675T3 (da) Xanthinderivater
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
PT992509E (pt) Novos derivados macrolidos
YU30603A (sh) Derivati premošćenog piperazina
DE69330601D1 (de) Serotoninergische ergolin derivate
ATE170851T1 (de) Guanidinothiazolederivate und ihre anwendung als h2-rezeptor-antagonisten
ATE238274T1 (de) Naphthalin derivate
AP2002002595A0 (en) Heterocyclic amide derivatives.
ATE218138T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
ATE258934T1 (de) Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition